- Poster
Hess D. et al. SAKK 65/16: TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: dose escalation part of a multicenter open-label phase I trial.
![Hess](/sites/default/files/inline-images/Dagmar_Hess_kl_0.jpg)
- Oral presentation
Joerger M. et al. SAKK 80/20: Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study.
![Joerger](/sites/default/files/inline-images/Markus_Joerger_kl_0.jpg)
![Froesch](/sites/default/files/inline-images/Froesch_Portrait_kl_0.png)
- Oral presentation
Rothschild S. et al. SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC) — A multicenter single-arm phase II trial.
![Rothschild](/sites/default/files/inline-images/Sacha_Rothschild_kl_0.jpg)
- Poster
Ribi K. et al. SAKK 95/16: Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland.
![Ribi](/sites/default/files/inline-images/Karin_Ribi_kl_0.jpg)
- Poster Stenner F. et al. SAKK 07/17: Optimizing Ipilimumab in RCC - Results from the SAKK 07/17 Nivolumab (N) + Ipilimumab (I) in mRCC.
![Stenner](/sites/default/files/inline-images/Frank%20Stenner_kl_0.jpg)
- Poster
Hasler-Strub U. et al. SAKK 25/14: Optimal Dose of Eribulin as 1st Line Treatment in Elderly Patients ≥ 70 Years with Advanced Breast Cancer: A Multicenter Phase II Trial.
![Hasler](/sites/default/files/inline-images/Ursula_Hasler_kl.jpg)
Please find more information on the ESMO website.